代表文章:
1.Chidamide in relapsed or refractory peripheral T cell lymphoma: amulticenter real-world study in China,Journal of Hematology & Oncology (2017) 10:69 2.Primary breast diffuse large B-cell lymphoma in the rituximab era:Therapeutic strategies and patterns of failure. Cancer Sci.2018;109:3943–3952. 3.Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1):a multicentre, single-arm, phase 2 trial, Lancet Haematol, 2019.1, 6: 12~19. 4.BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci. Transl. Med. 11,eaaw9414 (2019).